logo

Chinese Science Bulletin, Volume 65 , Issue 22 : 2326-2333(2020) https://doi.org/10.1360/TB-2020-0194

Recent research for COVID-19 drugs and therapies

More info
  • ReceivedFeb 28, 2020
  • AcceptedApr 2, 2020
  • PublishedApr 3, 2020

Abstract

The sudden outbreak of COVID-19 is causing a severe health crisis to China and the world. The rapid spread coronavirus worldwide highlights the urgent need to find effective drugs and therapies to fight the COVID-19 and related diseases such as acute respiratory disease. Based on the current knowledge on the structure, pathogenic mechanism and pharmacy of coronavirus and previous understanding and experience in treating similar diseases, researchers are testing and screening the approved broad-spectrum antiviral drugs and compounds, and investigating new specific drugs aiming at curing COVID-19. Facing the coronavirus pandemic, it is essential methods and strategies to review existing broad-spectrum antiviral drugs and screen possible effective medicines through some compounds database or repository of structured medical information. Till now, scientists have proposed hundreds of possible drug candidates in a short period of time.

This article summarized the potential drugs and treatments proposed by scientists, pharmaceutical industries, and clinicians through literature survey on PubMed—a medical academic database, two clinical trials databases, and internet information published before February 16th, 2020. Then a system review and analysis on the development situations and trends about COVID-19 drugs and therapies were carried out.

According to the documents published, scientists and doctors have focused on several possible categories of drugs, including: (1) Chemical compounds, such as nucleoside analogues, protease inhibitors, and other antiviral drugs with multiple mechanisms; (2) biologics, such as monoclonal antibodies, interferon, peptides, plasma of recovered patients and some new kinds of therapies; (3) traditional Chinese medicines, such as some syndrome differentiation therapies. Now, nearly 100 agents or therapies have entered into the clinic research processes and some of them have arrived at the IV phase of clinical trials.

Due to the considerable previous experiences and understands that have been accumulated in the researches on SARS-nCoV, Ebola, MERS, and AIDS, with the help of advanced biotechnology and medical technology, scientists can respond faster than ever before, and have investigated a variety of potential treatment options. For example, Remdesivir, which was originally targeted at Ebola virus, Kaletra, which has been used for the treatment of AIDS, Chloroquine, a typical drug used as antimalarial long time ago, glucocorticoids, a common therapies method used to combat SARS, washed microbiota transplantation and Mesenchymal Stem Cell, emerging biological therapies, and combination of multiple drugs or combination of traditional Chinese medicines and modern medicines, are bringing hope to treat COVID-19.

Now scientists have proposed several drug candidates (e.g., Remdesivir, Kaletra, Arbidol and Chloroquine) that could be the potential anti-coronavirus agents. All of these drugs are under study in the late phases of clinical trials. While Remdesivir and Kaletra have already shown positive effect on COVID-19 related disease at personalized level. Traditional Chinese Medicines treatment with syndrome differentiation combined with modern medicines also shows a good effect. A considerable number of candidate drugs have shown good results in vitro cell tests on COVID-19. Currently, the follow-up animal tests, toxicology tests, and human clinical trials are in progress at various stages.

After a period of clinical application research and further validation research on the clinical effect, safety, dosage and indications of these candidate drugs, it is expected that more drugs with significant efficacy will emerge. Finally, we will defeat COVID-19, and the public will live in a healthy and peaceful world.


Funded by

中国科学院生态环境研究中心城市与区域生态国家重点实验室开放基金(SKLURE2018-2-3)


References

[1] Li H, Wang Y M, Xu J Y, et al. Potential antiviral therapeutics for 2019 novel coronavirus (in Chinese). Chin J Tuberc Respir Dis, 2020, 43: 170–172 [李辉, 王业明, 徐九洋, 等. 2019新型冠状病毒抗病毒治疗有药可期. 中华结核和呼吸杂志, 2020, 43: 170–172]. Google Scholar

[2] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends, 2020, 14: 69-71 CrossRef Google Scholar

[3] Li G D, Clercq E D. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 2020, 19: 149–150. Google Scholar

[4] Liu W, Morse J S, Lalonde T, et al. Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem, 2020, 21: 730–738. Google Scholar

[5] Wang K J, Shi L M, He L, et al. New opportunity for Chinese pharmaceutical R&D: Systematic drug repurposing based on big data (in Chinese). Chin Sci Bull, 2014, 59: 1790-1796 CrossRef Google Scholar

[6] Sun T L, Pei J F. Drug design and drug information in the big data era (in Chinese). Chin Sci Bull, 2015, 60: 689-693 CrossRef Google Scholar

[7] Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 2020, 395: e30-e31 CrossRef Google Scholar

[8] Zumla A, Hui D S, Azhar E I, et al. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option. Lancet, 2020, 395: e35-e36 CrossRef Google Scholar

[9] Holshue M L, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the united states. N Engl J Med, 2020, 382: 929–936. Google Scholar

[10] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30: 269-271 CrossRef Google Scholar

[11] de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of mers-cov infection. Proc Natl Acad Sci USA, 2020, 117: 6771-6776 CrossRef Google Scholar

[12] Sheahan T P, Sims A C, Leist S R, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against mers-cov. Nat Commun, 2020, 11: 222 CrossRef Google Scholar

[13] Cheng Y, Liu J, Li Y, et al. Ebola virus disease: Virology, pathogenesis, therapy, and vaccines (in Chinese). Chin Sci Bull, 2014, 59: 2889-2899 CrossRef Google Scholar

[14] van Vonderen M G A, Bos J C, Prins J M, et al. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth J Med, 2003, 61: 238–241. Google Scholar

[15] Gross A E, Bryson M L. Oral ribavirin for the treatment of noninfluenza respiratory viral infections. Ann Pharmacother, 2015, 49: 1125-1135 CrossRef Google Scholar

[16] Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in guinea. PLoS Med, 2016, 13: e1001967. Google Scholar

[17] Offord C. Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand. The Scientist, 2020. https://www.the-scientist.com/news-opinion/flu-and-anti-hiv-drugs-show-efficacy-against-coronavirus-67052. Google Scholar

[18] Lin S, Shen R N, Guo X S. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to Severe Acute Respiratory Syndrome coronavirus 2 proteases. BioRxiv, 2020, doi: https://doi.org/10.1101/2020.01.31.929695. Google Scholar

[19] Lim J, Jeon S, Shin H Y, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci, 2020, 35: e79 CrossRef Google Scholar

[20] Tian X L, Li C, Huang A L, et al. Potent binding of 2019 novel coronavirus spike protein by a sars coronavirus-specific human monoclonal antibody. BioRxiv, 2020, doi: https://doi.org/10.1101/2020.01.28.923011. Google Scholar

[21] Xu Z C, Zhao K T, Jiang Y A, et al. Development of antiviral drugs against hepatitis B virus (in Chinese). Chin Sci Bull, 2019, 64: 3123-3141 CrossRef Google Scholar

[22] Savarino A, Boelaert J R, Cassone A, et al. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis, 2003, 3: 722–727. Google Scholar

[23] Vincent M J, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, 2005, 2: 69 CrossRef Google Scholar

[24] Colson P, Rolain J M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents, 2020, 55: 105923. Google Scholar

[25] Rong N H, Zhao Y P, Rong P J, et al. Cherish civilization roots, draw on other civilizations, be forward-thinking: Globalization of Chinese medicine (in Chinese). Chin Sci Bull, 2019, 64: 2672-2676 CrossRef Google Scholar

[26] Wang Y G, Qi W S, Ma J J, et al. TCM clinical characteristics and threpy with syndrome differentiation of 2019-nCoV pneumonia (in Chinese). J Tradit Chin Med, 2020, http://kns.cnki.net/kcms/detail/11.2166.R.20200129.1258.002.html [王玉光, 齐文升, 马家驹, 等. 新型冠状病毒(2019-nCoV)肺炎中医临床特征与辨证治疗初探. 中医杂志, 2020, http://kns.cnki.net/kcms/detail/11.2166.R.20200129.1258.002.html]. Google Scholar

[27] Chen R, Luo Y P, Xu X H, et al. TCM treatment and typical case analysis for novel coronavirus pneumonia based on 52 cases in Wuhan area (in Chinese) J Tradit Chin Med, 2020, http://kns.cnki.net/kcms/detail/11.2166.R.20200220.1443.002.html [陈瑞, 罗亚萍, 徐勋华, 等. 基于武汉地区52例新型冠状病毒肺炎的中医诊治初探及典型病案分析. 中医杂志, 2020, http://kns.cnki.net/kcms/detail/11.2166.R.20200220.1443.002.html]. Google Scholar

[28] Fan F Y, Fan X R, Wang X Z, et al. TCM characteristics and treatment to novel coronavirus pneumonia in Hunan (in Chinese). J Tradit Chin Med, 2020, http://kns.cnki.net/kcms/detail/11.2166.r.20200206.1256.004.html [范伏元, 樊新荣, 王莘智, 等. 从“湿毒夹燥”谈湖南新型冠状病毒感染的肺炎的中医特点及防治. 中医杂志, 2020, http://kns.cnki.net/kcms/detail/11.2166.r.20200206.1256.004.html]. Google Scholar

[29] Li J S, Li S Y, Xie Y. Ideas and methods of TCM syndrome differentiation and treatment for novel coronavirus pneumonia in Henan Province (in Chinese). Acta Chin Med, 2020, 35: 453–457 [李建生, 李素云, 谢洋. 河南省新型冠状病毒肺炎中医辨证治疗思路与方法. 中医学报, 2020, 35: 453–457]. Google Scholar

[30] Miao Q, Cong X D, Wang B, et al. Thought about the novel coronavirus pneumonia with TCM theory (in Chinese). J Tradit Chin Med, 2020, 61: 286–288 [苗青, 丛晓东, 王冰, 等. 新型冠状病毒感染肺炎的中医认识与思考. 中医杂志, 2020, 61: 286–288]. Google Scholar

[31] Ma J J, Chen M, Wang Y G. Introduction of TCM treatment to novel coronavirus (2019-nCoV) (in Chinese). Beijing J Tradit Chin Med, 2020, http://kns.cnki.net/kcms/detail/11.5635.R.20200207.1616.002.html [马家驹, 陈明, 王玉光. 新型冠状病毒(2019-nCoV)综合征中医证治述要. 北京中医药, 2020, http://kns.cnki.net/kcms/detail/11.5635.R.20200207.1616.002.html]. Google Scholar

[32] Wang C C, Wu S, Jiang L J, et al. Comprehensive analysis of TCM diagnosis and treatment schemes for COVID-19 in all regions of China (in Chinese). World Sci Technol/Mod Tradit Chin Med Mat Med, 2020, http://kns.cnki.net/kcms/detail/11.5699.R.20200225.1702.006.html [王传池, 吴珊, 江丽杰, 等. 全国各地区新型冠状病毒肺炎中医药诊治方案综合分析. 世界科学技术-中医药现代化, 2020, http://kns.cnki.net/kcms/detail/11.5699.R.20200225.1702.006.html]. Google Scholar

  • Table 1   Clinical trials of novel coronavirus drugs or therapies

    临床试验名称

    药物或疗法(研发机构)

    临床试验发起/合作机构

    临床试验阶段

    开始日期

    主要结果评价数据收集结束日期

    全部结果评价数据收集结束日期

    3种抗病毒药物治疗新冠病毒肺炎的比较

    阿比多尔、奥司他韦、洛匹那韦/利托那韦(雅培)

    华中科技大学附属同济医院

    4

    2020/2/1

    2020/6/1

    2020/7/1

    新冠病毒肺炎的干扰素雾化治疗

    阿比多尔联合干扰素雾化

    华中科技大学附属同济医院

    4

    2020/2/1

    2020/6/1

    2020/7/1

    不同激素剂量治疗新冠病毒重症肺炎的疗效

    甲泼尼龙

    华中科技大学附属同济医院

    4

    2020/2/1

    2020/6/1

    2020/7/1

    阿比多尔治疗新型冠状病毒肺炎的临床研究

    阿比多尔

    上海交通大学医学院

    附属瑞金医院瞿介明

    4

    2020/2/7

    2020/7/1

    2020/12/30

    瑞德西韦治疗新冠病毒肺炎轻中度患者的疗效和安全性

    瑞德西韦(吉利德)

    首都医科大学/中国医学科学院

    3

    2020/2/5

    2020/4/10

    2020/4/27

    ASC09F/利托那韦对新冠病毒肺炎的疗效

    ASC09/利托那韦(歌礼、雅培)

    华中科技大学附属同济医院

    3

    2020/2/1

    2020/5/1

    2020/7/1

    瑞德西韦治疗新冠病毒肺炎的疗效和安全性

    瑞德西韦(吉利德)

    首都医科大学(中日友好医院)

    3

    2020/2/6

    2020/4/3

    2020/5/1

    达芦那韦/考比司他治疗新冠病毒肺炎的疗效和安全性

    达芦那韦/考比司他(强生)

    上海市公共卫生临床中心

    3

    2020/1/30

    2020/8/31

    2020/12/31

    羟氯喹治疗新冠病毒肺炎的疗效和安全性

    羟氯喹

    上海市公共卫生临床中心

    3

    2020/2/6

    2020/8/31

    2020/12/31

    糖皮质激素治疗新型冠状病毒严重急性呼吸衰竭的重症患者

    甲泼尼龙

    北京协和医院/东南大学中大医院、武汉大学中南医院、武汉大学人民医院

    2、3

    2020/1/26

    2020/4/25

    2020/12/25

    静脉注射免疫球蛋白对新冠病毒重症肺炎的疗效

    免疫球蛋白静脉注射

    北京协和医院/华中科技大学附属同济医院

    2、3

    2020/2/10

    2020/4/30

    2020/6/30

    新冠病毒的免疫调节治疗

    PD-1抗体、胸腺肽

    东南大学

    2

    2020/2/10

    2020/4/30

    2020/10/31

    脐带间充干细胞治疗新冠病毒肺炎

    脐带间充干细胞

    武汉大学中南医院彭志勇/拓华生物科技有限公司

    2

    2020/2/6

    2020/4/30

    2020/9/30

    维生素C输液治疗严重的新冠病毒肺炎

    维生素C

    武汉大学中南医院彭志勇

    2

    2020/2/10

    2020/9/30

    2020/9/30

    间充质干细胞治疗新冠病毒肺炎

    间充质干细胞

    北京302医院/浙江生创精准医疗科技有限公司、武汉火神山医院、天津海河医院、中源协和细胞基因工程股份有限公司、深圳市第三人民医、中山大学第五附属医院

    1

    2020/2/1

    2020/12/1

    2021/12/1

    洗涤菌群移植治疗新冠病毒肺炎

    洗涤菌群移植

    南京医科大学第二附属医院

    不适用

    2020/2/2

    2020/4/2

    2020/4/16

    治愈患者的免疫球蛋白治疗急性重症新冠病毒肺炎

    免疫球蛋白

    武汉协和医院

    不适用

    2020/2/17

    2020/4/30

    2020/5/31

    评价和比较ASC09/利托那韦和洛匹那韦/利托那韦用于新型冠状病毒感染的疗效和安全性

    ASC09/利托那韦(歌礼、雅培)、洛匹那韦/利托那韦(雅培)

    浙江大学第一附属医院/

    歌礼制药有限公司

    不适用

    2020/2/7

    2020/5/31

    2020/6/30

    中药对新冠病毒感染的治疗和预防

    中药颗粒

    北京302医院

    不适用

    2020/1/22

    2021/1/22

    2021/1/22

    “临床试验阶段不适用”表示该临床试验不适用于FDA定义的临床试验阶段, 包括一些设备试验或行为干涉试验

Copyright 2020  CHINA SCIENCE PUBLISHING & MEDIA LTD.  中国科技出版传媒股份有限公司  版权所有

京ICP备14028887号-23       京公网安备11010102003388号